Ranibizumab ophthalmic

Generic name: Ranibizumab (ophthalmic)
Dosage form: intravitreal solution (10 mg/mL; 100 mg/mL; 6 mg/mL; eqrn 10 mg/ml; eqrn 6 mg/ml; nuna 10 mg/mL)
Drug class: Anti-angiogenic ophthalmic agents

Usage of Ranibizumab ophthalmic

Ranibizumab ophthalmic (for the eyes) is used in adults to treat the "wet form" of age-related macular degeneration. Ranibizumab is also used in adults to treat swelling in the retina caused by diabetes, or a blockage in blood vessels.

Ranibizumab can also be used in adults to treat diabetic retinopathy, and myopia caused by abnormal growth of new blood vessels in the retina.

Ranibizumab may also be used for purposes not listed in this medication guide.

Ranibizumab ophthalmic side effects

Get emergency medical help if you have signs of an allergic Reaction: hives, difficult breathing, swelling of your face, lips, tongue, or throat.

Ranibizumab may cause serious side effects. Call your doctor at once if you have:

increased eye pain, swelling, or redness in your eye;

vision loss, sensitivity to light;

blurred vision, seeing halos around lights;

feeling like something is in your eye;

discharge or watery eyes;

sudden changes in your vision, seeing flashes of light; or

a "spider webs" appearance in your vision.

Common side effects of ranibizumab may include:

eye pain;

sensitivity to light;

"floaters" in your vision;

increased pressure inside the eye; or

eye redness or a blood spot on the white of your eye.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Before taking Ranibizumab ophthalmic

You should not receive ranibizumab if you are allergic to it, or if you have:

swelling, redness, pain inside or around your eyes; or

any type of infection in or around your eyes.

Tell your doctor if you have or have ever HAD:

an eye infection;

retinal detachment;

a heart attack, or stroke;

glaucoma or other condition that increases pressure inside your eyes; or

taken certain other medicines that can increase bleeding risk such as Warfarin, aspirin, or nonsteroidal anti-inflammatory drugs (NSAID).

It is not known if ranibizumab will harm an unborn baby. Use effective birth control while using ranibizumab and for at least 12 months after your last dose. Tell your doctor if you are pregnant or plan to become pregnant.

Ask a doctor if it is safe to breastfeed while using ranibizumab.

Relate drugs

How to use Ranibizumab ophthalmic

Usual Adult Dose for Macular Degeneration:

0.5 mg via intravitreal injection once a month (approximately 28 days)Use: Neovascular (wet) age-related macular degeneration (AMD)

Usual Adult Dose for Diabetic Retinopathy:

-DME and Diabetic Retinopathy with DME:0.3 mg via intravitreal injection once a month (approximately 28 days)-Macular Edema following RVO:0.5 mg via intravitreal injection once a month (approximately 28 days)Uses: Diabetic macular edema (DME); diabetic retinopathy with DME; macular edema following retinal vein occlusion (RVO)

Usual Adult Dose for Macular Edema:

Warnings

You should not receive ranibizumab if you have swelling, redness, pain inside your eyes, or any type of infection in or around your eyes.

Call your doctor at once if you have sudden vision problems, eye pain, redness, discharge, or watering in your eye, or if your eyes are more sensitive to light.

What other drugs will affect Ranibizumab ophthalmic

Medicine used in the eyes is not likely to be affected by other drugs you use. But many drugs can interact. Tell your doctor about all your current medicines, including prescription and over-the-counter medicines, vitamins, and herbal products.

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.